Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.
A global consensus published in The Lancet has officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a change with broad implications for diagnosis, care, and cardiometabolic screening.
The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
In the debut episode of Missed & Dismissed, Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, talks with Charis Chambers, MD, about PCOS, the push to rename it PMOS, and why diagnostic delays so often begin in adolescence.